AstraZeneca plc (LON:AZN)‘s stock had its “reduce” rating restated by HSBC Holdings plc in a research report issued on Monday. They presently have a GBX 4,100 ($52.95) target price on the biopharmaceutical company’s stock. HSBC Holdings plc’s target price indicates a potential downside of 14.41% from the company’s previous close.
A number of other analysts also recently weighed in on the stock. Credit Suisse Group reissued a “neutral” rating and set a GBX 4,700 ($60.70) target price on shares of AstraZeneca plc in a research report on Monday. Liberum Capital reissued a “buy” rating and set a GBX 4,800 ($61.99) target price on shares of AstraZeneca plc in a research report on Monday. J P Morgan Chase & Co reissued a “neutral” rating on shares of AstraZeneca plc in a research report on Friday. Citigroup Inc. reissued a “buy” rating on shares of AstraZeneca plc in a research report on Thursday. Finally, Natixis raised shares of AstraZeneca plc from a “neutral” rating to a “buy” rating and increased their target price for the company from GBX 5,000 ($64.57) to GBX 5,738 ($74.11) in a research report on Wednesday, September 6th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of GBX 4,944.27 ($63.85).
AstraZeneca plc (LON:AZN) opened at 4790.00 on Monday. The company’s 50-day moving average is GBX 4,593.39 and its 200-day moving average is GBX 4,871.66. The firm’s market cap is GBX 60.64 billion. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00.
AstraZeneca plc (LON:AZN) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $1.01. AstraZeneca plc had a net margin of 8.83% and a return on equity of 14.36%. On average, analysts forecast that AstraZeneca plc will post $3.75 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “AstraZeneca plc (AZN) Given “Reduce” Rating at HSBC Holdings plc” was published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.themarketsdaily.com/2017/09/11/astrazeneca-plc-azn-given-reduce-rating-at-hsbc-holdings-plc.html.
In related news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction on Thursday, July 27th. The shares were acquired at an average cost of GBX 4,370 ($56.44) per share, for a total transaction of £1,704.30 ($2,201.08).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.